Treat cancer and reverse fibrosis

We are a clinical-stage biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our pipeline of anti-Claudin-1 monoclonal antibodies and antibody-drug conjugates (ADCs).

Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing new treatments to those in need.

Transformative Claudin-1 antibodies

We are the world leader in developing anti-Claudin-1 treatment. Our first-in-class antibodies specifically target exposed Claudin-1 to open the stiff extracellular matrix, block disease signaling, and in cancer, selectively kill tumor cells.

R&D pipeline

We have developed a promising pipeline of anti-Claudin-1 antibodies. Our clinical candidates include monoclonal antibodies ALE.C04 for solid tumors and ALE.F02 for organ fibrosis, and ALE.P02, an antibody-drug conjugate (ADC) for squamous cancers. Beyond the clinical assets, our preclinical programs feature other anti-Claudin-1 ADCs, bispecific antibodies, and T-cell engagers.

Inspired leadership

Our carefully chosen team values collaboration, hard work and shares the belief that anti-Claudin-1 therapies will make a difference for patients. Our highly experienced leadership team is supported by a Board of Directors and a Scientific Advisory Board made up of industry veterans, entrepreneurs and esteemed scientists.

Alentis news

November 18, 2024

ALENTIS RECEIVES FDA FAST TRACK DESIGNATION FOR ALE.P02

November 12, 2024

ALENTIS RAISES $181M SERIES D FINANCING ROUND TO ADVANCE CLDN1 ADCS

October 2, 2024​

ALENTIS RECEIVED FDA IND CLEARANCE FOR ALE.P02, A NOVEL CLDN1-ADC